As targeted therapies' offer increases more and more in cancer treatment, besides treatment efficacy, it appears crucial to continue optimizing patients profiling with accurate testing in order to provide the right treatment for the right patient. The HER2 story illustrates and emphasizes the key role of a companion test to efficiently select patients.
HER2 testing interpretation improvement in France over the last 7 years has clearly contributed to reduce the economic burden of tumor misclassification. Between 2007 and 2014, the decrease of HER2 false-negative rate (from 4% to 2%) and HER 2 falsepositive rate (from 10% to 7%) saved 542 patient lives and 25 million EUR (€), mainly coming from drug savings.
Continued investment in improving HER2 testing accuracy would ensure therapeutic and economic efficiency of breast cancer treatments. Further analysis could be performed to evaluate the societal cost of HER2 testing inaccuracy.
Each year in France, more than 50,000 women are newly diagnosed with breast cancer and 90,000 HER2 tests are performed.
For HER2+ breast cancer patients, initiating the right treatment at an early stage increase the chance of survival and the accurate determination of HER2 status is clinically crucial.
Between 2007 and 2014, quality of HER2 testing improved significantly, leading to lower rates of HER2 status misclassified.
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Background

Objective
Conclusion
Methods
In an increasingly challenging environment within the French health care system, payers are interested to discuss the full value of a drug. A structured and standardized methodology was built in order to evaluate the public health impact of HER2 testing interpretation improvement in France since 2007. 
Results & Discussion
Data
Epidemiologic data were obtaining from the French National Cancer Institute (INCa). All breast cancer patients are considered to be tested.
The rate of HER2+ and HER2-are extracted from the "HER France" register developed by the French Association for Quality Assurance in Histopathology and Cytopathology (AFAQAP).
Twice a year, AFAQAP offers laboratories the opportunity to participate to external quality assessment (EQA) of HER2 expression in breast cancer. The rate of HER2 status misclassified (false-positive and false-negative) were assessed using results of EQA based on misreading/misinterpretation rate. Discordance due to technical error is not considered.
Current use of trastuzumab (Herceptin®) and bevacizumab (Avastin®) was assessed using quarterly Roche database for analyzing market shares. Drug efficacy data are based on their Summary of Product Characteristics (SmPC) a .
Cost
Cost analysis considered intervention costs, costs of premature death, life years lost and drug costs, focused on drug registered on the French costly drug list (like trastuzumab and bevacizumab). No discount rate on costs was applied in the model. Whatever the scenario tested, improvement in HER2 testing quality results in more lives saved than the base case scenario (most conservative), showing a minimal gain of 542 lives and a maximum gain of 1,580 lives -see Table 3 . Table 2 . FP results were assumed to generate unnecessary trastuzumab costs, a~6-month increase duration of treatment and no impact on clinical outcomes with similar disease-free survival rates between FP and truly HER2+ patients. FN results mainly lead to a shorter life-expectancy due to lack of targeted therapy and an increased risk of recurrence and progression to metastatic breast cancer (~40% relapse rate).
The improvement of HER2 testing interpretation between 2007 and 2017 saved 25 million EUR (€). These savings are mainly the result of HER2 false-positive rate decrease and more than 90% come from Herceptin cost. Cost savings of 4 million EUR (€) were also achieved by intervention cost, at the two breast cancer stagessee Figure 3 . 
